Schrodinger, Inc.
SDGR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SDGR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SDGR
Schrödinger, Inc. (SDGR) is a computational drug discovery and software company that combines its physics-based platform with AI to advance a pipeline of proprietary and collaborative drug programs, including two Phase 1 clinical candidates.
Key risk: Reliance on partnerships for pipeline
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Schrodinger, Inc..
Schrödinger, Inc. (SDGR) is a computational drug discovery and software company that combines its physics-based platform with AI to advance a pipeline of proprietary and collaborative drug programs, including two Phase 1 clinical candidates.
- Generated 2025 total revenue of $255.9 million, up 23.3% over 2024, and software revenue of $199.5 million, up 10.6% [sec · filed 2026-04-28].
- As of 2026-06-30, reported cash & equivalents of $292.9M, total revenue of $58.9M, net income of $6.0M, and shareholders' equity of $364.1M [sec].
- Presented encouraging initial Phase 1 clinical data for SGR-1505 (MALT1 inhibitor) in relapsed/refractory B-cell malignancies and is advancing SGR-3515 (Wee1/Myt1 co-inhibitor) in solid tumors [sec · filed 2026-04-28].
- Launched a new AI-powered conversational interface in its Maestro graphical interface and advanced its predictive toxicology initiative [sec · filed 2026-04-28].
- Entered into expanded research collaboration agreements with Ajax Therapeutics, Eli Lilly and Company, and Otsuka Pharmaceutical Co., Ltd. [sec · filed 2026-04-28].
What works
- Strong revenue growth: 2025 total revenue increased 23.3% year-over-year, driven by a 10.6% rise in software revenue [sec · filed 2026-04-28].
- Diversified collaboration model with multiple large pharma partners (Eli Lilly, Otsuka, Ajax) reduces single-program risk and provides milestone/royalty potential [sec · filed 2026-04-28].
- Cash position of $292.9M as of 2026-06-30 provides runway to fund operations and ongoing Phase 1 trials without near-term financing pressure [sec].
- Platform innovation (AI conversational interface, predictive toxicology) strengthens competitive moat in computational drug discovery [sec · filed 2026-04-28].
What to weigh
- Company does not intend to initiate additional clinical trials beyond ongoing Phase 1 studies for SGR-1505 and SGR-3515, relying on partnerships for further development [sec_mda · as of 2026-05-05].
- Dependence on collaborators for advancing programs beyond discovery stage; company does not control collaborators' development decisions [sec_mda · as of 2026-02-25].
- Future capital requirements are uncertain and may require additional equity or debt financing, especially if milestones or distributions from equity stakes are delayed [sec_mda · as of 2026-08-05].
- Revenue concentration in software segment (78% of total 2025 revenue) exposes the company to subscription renewal and market adoption risks [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
2025 total revenue growth and software revenue growth
“Generated 2025 total revenue of $255.9 million, up 23.3 percent over 2024 • Generated 2025 software revenue of $199.5 million, up 10.6 percent over 2024”
SEC filings · April 28, 2026
Phase 1 data for SGR-1505 and advancement of SGR-3515
“Presented encouraging initial Phase 1 clinical data for SGR-1505, our MALT1 inhibitor, in patients with relapsed or refractory B-cell malignancies, at three medical conferences • Advanced the Phase 1 clinical trial of SGR-3515, our Wee1/Myt1 co-inhibitor, in patients with advanced solid tumors”
SEC filings · April 28, 2026
Plan to seek partnerships for SGR-1505 and SGR-3515 beyond Phase 1
“We plan to explore strategic partnerships for the SGR-1505 and SGR-3515 programs to advance the development of these programs beyond our ongoing Phase 1 clinical trials.”
SEC MD&A · May 5, 2026
Cash and marketable securities position as of March 31, 2026
“As of March 31, 2026, we had cash, cash equivalents, restricted cash, and marketable securities of $406.4 million.”
SEC MD&A · May 5, 2026
Risks & what to watch (4)›
Key risks
- Reliance on partnerships for pipeline — Company does not plan to independently advance programs beyond Phase 1; future value depends on partners' decisions and execution [sec_mda · as of 2026-05-05].
- Uncertain capital needs — May require additional equity or debt financing; cash runway depends on milestone timing and distributions from equity stakes [sec_mda · as of 2026-08-05].
- Software revenue concentration — 78% of 2025 revenue from software; subscription-based model faces renewal and competitive pressures [sec · filed 2026-04-28].
- No control over collaborator programs — Company does not control collaborators' clinical or commercial decisions, impacting milestone and royalty timelines [sec_mda · as of 2026-02-25].
What to watch
- Progress of Phase 1 dose-escalation trials for SGR-1505 and SGR-3515, including any new clinical data readouts [sec · filed 2026-04-28].
- Announcement of strategic partnerships for SGR-1505 and SGR-3515 to fund further development [sec_mda · as of 2026-05-05].
- Software revenue growth trajectory and adoption of new AI-powered features in Maestro [sec · filed 2026-04-28].
- Cash runway updates; as of March 31, 2026, management believed existing cash would fund operations for at least 24 months [sec_mda · as of 2026-05-05].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Schrodinger, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Schrodinger, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
37.7 months
D/E 0.95 · 1% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
0 buys · 12 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
226
Total value held
$638.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,678,560 | $109.9M |
| gates foundation trust | 6,981,664 | $79.3M |
| vanguard capital management llc | 5,208,748 | $59.2M |
| vanguard portfolio management llc | 3,862,197 | $43.9M |
| amova asset management americas, inc. | 3,190,837 | $36.2M |
| massachusetts financial services co /ma/ | 2,684,692 | $30.5M |
| state street corp | 2,191,427 | $24.9M |
| ark investment management llc | 2,067,135 | $23.5M |
| morgan stanley | 1,371,199 | $15.6M |
| geode capital management, llc | 1,351,496 | $15.4M |
Showing top 10 of 226 institutional holders of Schrodinger, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 27.4%
- Days to cover
- 10.1
- Shares short
- 11,112,514
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SDGR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Schrodinger, Inc.?
Schrödinger, Inc. (SDGR) is a computational drug discovery and software company that combines its physics-based platform with AI to advance a pipeline of proprietary and collaborative drug programs, including two Phase 1 clinical candidates.
What is Schrodinger, Inc.'s lead drug candidate?
Schrodinger, Inc.'s most advanced tracked candidate is sgr-1505 (Phase 1) for relapsed or refractory B-cell lymphomas.
Who is the CEO of Schrodinger, Inc.?
Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger, Inc. (SDGR).
Where is Schrodinger, Inc. headquartered?
Schrodinger, Inc. (SDGR) is headquartered in New York, NY, United States.
What therapeutic areas does Schrodinger, Inc. focus on?
Schrodinger, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.